BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 9308559)

  • 1. Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma.
    Barrett TL; Smith KJ; Hodge JJ; Butler R; Hall FW; Skelton HG
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):430-7. PubMed ID: 9308559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical nuclear staining for p53, PCNA, Ki-67 and bcl-2 in different histologic variants of basal cell carcinoma.
    Mateoiu C; Pirici A; Bogdan F
    Rom J Morphol Embryol; 2011; 52(1 Suppl):315-9. PubMed ID: 21424069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and P53.
    Abdelsayed RA; Guijarro-Rojas M; Ibrahim NA; Sangueza OP
    J Cutan Pathol; 2000 Apr; 27(4):169-75. PubMed ID: 10774937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical staining for Ber-EP4, p53, proliferating cell nuclear antigen, Ki-67, bcl-2, CD34, and factor XIIIa in nevus sebaceus.
    Barrett TL; Smith KJ; Williams J; Corner SW; Hodge JJ; Skelton HG
    Mod Pathol; 1999 May; 12(5):450-5. PubMed ID: 10349981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p16 Protein in Cutaneous Basal Cell Carcinoma: Still far from Being Clearly Understood.
    Bartoš V
    Acta Dermatovenerol Croat; 2020 Jul; 28(1):43-44. PubMed ID: 32650852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microcystic adnexal carcinoma: an immunohistochemical study including markers of proliferation and apoptosis.
    Smith KJ; Williams J; Corbett D; Skelton H
    Am J Surg Pathol; 2001 Apr; 25(4):464-71. PubMed ID: 11257620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamin expression in normal human skin, actinic keratosis, squamous cell carcinoma and basal cell carcinoma.
    Tilli CM; Ramaekers FC; Broers JL; Hutchison CJ; Neumann HA
    Br J Dermatol; 2003 Jan; 148(1):102-9. PubMed ID: 12534602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical prognostic criteria in xeroderma pigmentosum.
    Karakok M; Turkmen A; Bekerecioglu M; Koçer NE
    Int J Dermatol; 2010 Nov; 49(11):1266-71. PubMed ID: 21038547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of PTCH1, COX-2, p53, and Ki-67 protein expression in basal cell carcinomas of nodular and superficial subtypes arising on the head and trunk.
    Khalesi M; Waterhouse M; Whiteman DC; Johns R; Rosendahl C; Hackett T; Pollak T; Kimlin MG; Hacker E; Neale RE;
    Int J Dermatol; 2016 Oct; 55(10):1096-105. PubMed ID: 27126210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation.
    Ionescu DN; Arida M; Jukic DM
    Arch Pathol Lab Med; 2006 Jan; 130(1):45-51. PubMed ID: 16390237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
    Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
    Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basaloid/follicular hyperplasia overlying connective tissue/mesenchymal hamartomas simulating basal cell carcinomas.
    Stashower ME; Smith K; Corbett D; Skelton HG
    J Am Acad Dermatol; 2001 Dec; 45(6):886-91. PubMed ID: 11712034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma.
    Ansarin H; Daliri M; Soltani-Arabshahi R
    Eur J Dermatol; 2006; 16(5):543-7. PubMed ID: 17101476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Aug; 86(2):192-9. PubMed ID: 12144828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
    Vidal D; Matías-Guiu X; Alomar A
    Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.
    Kindblom LG; Ahldén M; Meis-Kindblom JM; Stenman G
    Virchows Arch; 1995; 427(1):19-26. PubMed ID: 7551341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of p53 and Ki67 Expression Profiles in Basal Cell Carcinomas in a Usual and an Unusual Location.
    Süngü N; Kiran MM; Tatli Doğan H; Kiliçarslan A; Karakök E; Akyol M
    Turk Patoloji Derg; 2018; 34(2):165-170. PubMed ID: 29630084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p53, D2-40 and α-smooth muscle actin in different histological subtypes of facial basal cell carcinoma.
    Mercut R; Ciurea ME; Mărgăritescu C; Popescu SM; Crăitoiu MM; Cotoi OS; Voinescu DC
    Rom J Morphol Embryol; 2014; 55(2):263-72. PubMed ID: 24969973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunomorphological features of cutaneous basal-cell carcinoma].
    Chuprov IN
    Vopr Onkol; 2008; 54(6):715-9. PubMed ID: 19241845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers.
    Haitel A; Wiener HG; Blaschitz U; Marberger M; Susani M
    Cancer; 1999 Apr; 85(7):1593-8. PubMed ID: 10193951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.